Cargando…
Impact of the introduction of the AMNOG law on launch delays of new drugs in Germany: a comment
Autor principal: | Gandjour, Afschin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10406710/ https://www.ncbi.nlm.nih.gov/pubmed/37354349 http://dx.doi.org/10.1007/s10198-023-01607-5 |
Ejemplares similares
-
How Far is Germany From Value-Based Pricing 10 Years After the Introduction of AMNOG?
por: Dintsios, Charalabos-Markos, et al.
Publicado: (2021) -
Willingness to pay for new medicines: a step towards narrowing the gap between NICE and IQWiG
por: Gandjour, Afschin
Publicado: (2020) -
Predictors of negotiated prices for new drugs in Germany
por: Gandjour, Afschin, et al.
Publicado: (2020) -
Demonstrating the value of cancer biomarkers at the population level
por: Gandjour, Afschin
Publicado: (2022) -
A Model-Based Estimate of the Cost-Effectiveness Threshold in Germany
por: Gandjour, Afschin
Publicado: (2023)